Methylation profiles of hereditary and sporadic ovarian cancer
- 31 August 2010
- journal article
- Published by Wiley in Histopathology
- Vol. 57 (3) , 363-370
Abstract
Bol G M, Suijkerbuijk K P M, Bart J, Vooijs M, van der Wall E & van Diest P J (2010) Histopathology 57, 363–370 Methylation profiles of hereditary and sporadic ovarian cancerAims: Tumour suppressor gene silencing through promoter hypermethylation plays an important role in oncogenesis. Carcinogenesis of hereditary cancers usually differs from that of their sporadic counterparts, but methylation has hardly been studied in hereditary ovarian cancer. The aim of this study was to investigate promoter methylation of a set of common tumour suppressor genes in BRCA1‐related ovarian cancer in comparison with sporadic ovarian cancer.Methods and results: Methylation‐specific multiplex ligation‐dependent probe amplification was used to assess the extent of promoter methylation of 24 different tumour suppressor genes in BRCA1‐associated (n = 25) and matched sporadic ovarian tumours (n = 50). A cumulative methylation index (CMI) was calculated and differences between individual genes were analysed. There was no significant difference in cumulative methylation between BRCA1‐associated and sporadic ovarian carcinomas (median CMI 108; CMI 110; P = 0.86). Also, methylation patterns of individual genes did not show distinct differences after correction for multiple comparisons. CDH13, GSTP1 and RASSF1 were frequently methylated in both sporadic and hereditary ovarian cancers. BRCA1 methylation occurred in 14% of sporadic tumours, but was not detected in BRCA1‐associated tumours.Conclusions: CDH13, GSTP1 and RASSF1 are frequently methylated in both sporadic and BRCA1‐associated ovarian cancers. Interestingly, methylation of BRCA1, while frequent in sporadic ovarian cancer, never occurred in the hereditary group. BRCA1‐associated ovarian cancers mimic their sporadic counterparts in extent and pattern of promoter methylation of several common tumour suppressor genes. This finding could have implications for future chemotherapy regimens based on epigenetic changes.Keywords
This publication has 40 references indexed in Scilit:
- Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomasMolecular Cancer, 2009
- Methylation is less abundant in BRCA1-associated compared with sporadic breast cancerAnnals of Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targetsMolecular Cancer, 2007
- Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic studyGut, 2007
- Methylation profile in benign, borderline and malignant ovarian tumorsJournal of Cancer Research and Clinical Oncology, 2006
- Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological dataJournal of Clinical Pathology, 2006
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- Aberrant CpG-island methylation has non-random and tumour-type–specific patternsNature Genetics, 2000